These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 23830855)

  • 1. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: a meta-analysis.
    De Herdt A; Wampers M; Vancampfort D; De Hert M; Vanhees L; Demunter H; Van Bouwel L; Brunner E; Probst M
    Schizophr Res; 2013 Sep; 149(1-3):48-55. PubMed ID: 23830855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and to Be Most Promising for Predictive Algorithms for Conversion to Psychosis: A Meta-Analysis.
    Hauser M; Zhang JP; Sheridan EM; Burdick KE; Mogil R; Kane JM; Auther A; Carrión RE; Cornblatt BA; Correll CU
    J Clin Psychiatry; 2017 Jan; 78(1):e28-e40. PubMed ID: 28129494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline.
    Carrión RE; Walder DJ; Auther AM; McLaughlin D; Zyla HO; Adelsheim S; Calkins R; Carter CS; McFarland B; Melton R; Niendam T; Ragland JD; Sale TG; Taylor SF; McFarlane WR; Cornblatt BA
    J Psychiatr Res; 2018 Jan; 96():231-238. PubMed ID: 29121595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
    Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
    Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive function as a possible marker for remission from clinical high risk for psychosis.
    Lee TY; Shin YS; Shin NY; Kim SN; Jang JH; Kang DH; Kwon JS
    Schizophr Res; 2014 Mar; 153(1-3):48-53. PubMed ID: 24529365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social cognitive functioning in prodromal psychosis: A meta-analysis.
    Lee TY; Hong SB; Shin NY; Kwon JS
    Schizophr Res; 2015 May; 164(1-3):28-34. PubMed ID: 25749019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive dysfunction in subjects at clinical high risk for psychosis: A meta-analysis.
    Zheng W; Zhang QE; Cai DB; Ng CH; Ungvari GS; Ning YP; Xiang YT
    J Psychiatr Res; 2018 Aug; 103():38-45. PubMed ID: 29772485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study.
    Seidman LJ; Shapiro DI; Stone WS; Woodberry KA; Ronzio A; Cornblatt BA; Addington J; Bearden CE; Cadenhead KS; Cannon TD; Mathalon DH; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW
    JAMA Psychiatry; 2016 Dec; 73(12):1239-1248. PubMed ID: 27806157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.
    Seidman LJ; Giuliano AJ; Meyer EC; Addington J; Cadenhead KS; Cannon TD; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW; Bearden CE; Christensen BK; Hawkins K; Heaton R; Keefe RS; Heinssen R; Cornblatt BA;
    Arch Gen Psychiatry; 2010 Jun; 67(6):578-88. PubMed ID: 20530007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis.
    Carrión RE; McLaughlin D; Auther AM; Olsen R; Correll CU; Cornblatt BA
    Psychol Med; 2015 Nov; 45(15):3341-54. PubMed ID: 26169626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection and early treatment of subjects at high risk of clinical psychosis: Definitions and recommendations].
    Michel C; Toffel E; Schmidt SJ; Eliez S; Armando M; Solida-Tozzi A; Schultze-Lutter F; Debbané M
    Encephale; 2017 May; 43(3):292-297. PubMed ID: 28347521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between negative symptoms and MATRICS neurocognitive domains: A meta-analysis and systematic review.
    Au-Yeung C; Penney D; Rae J; Carling H; Lassman L; Lepage M
    Prog Neuropsychopharmacol Biol Psychiatry; 2023 Dec; 127():110833. PubMed ID: 37482283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Various neurocognitive deficits and conversion risk in individuals at clinical high risk for psychosis.
    Mourik K; Decrescenzo P; Brucato G; Gill KE; Arndt L; Kimhy D; Keilp JG; Girgis RR
    Early Interv Psychiatry; 2017 Jun; 11(3):250-254. PubMed ID: 26663764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
    Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
    Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating cognitive deficits and symptomatology across pre-morbid adjustment patterns in first-episode psychosis.
    Béchard-Evans L; Iyer S; Lepage M; Joober R; Malla A
    Psychol Med; 2010 May; 40(5):749-59. PubMed ID: 19732482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?
    Becker HE; Nieman DH; Wiltink S; Dingemans PM; van de Fliert JR; Velthorst E; de Haan L; van Amelsvoort TA; Linszen DH
    Psychol Med; 2010 Oct; 40(10):1599-606. PubMed ID: 20132582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis.
    Brewer WJ; Francey SM; Wood SJ; Jackson HJ; Pantelis C; Phillips LJ; Yung AR; Anderson VA; McGorry PD
    Am J Psychiatry; 2005 Jan; 162(1):71-8. PubMed ID: 15625204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive deficits profiles in the first-episode of schizophrenia, clinical high risk of psychosis, and genetically high-risk of psychosis.
    Dong F; Mao Z; Ding Y; Wang L; Bo Q; Li F; Wang F; Wang C
    Front Psychiatry; 2023; 14():1292141. PubMed ID: 38146278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis.
    Lin A; Wood SJ; Nelson B; Brewer WJ; Spiliotacopoulos D; Bruxner A; Broussard C; Pantelis C; Yung AR
    Schizophr Res; 2011 Oct; 132(1):1-7. PubMed ID: 21763109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.